Program
QRL-101
A development code. Also written as “QRL-101 Dose A” and “QRL-101 Dose B”.
Its studies are mostly in Amyotrophic Lateral Sclerosis, led by QurAlis.
Furthest: phase 1, since Dec 19, 20226 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| QurAlis | 60 open or running | phase 1since Dec 19, 2022 | Dec 19, 2022 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 19, 2022First study: phase 1 study in Healthy VolunteersFirst studyNCT05667779 · 88 enrolled · Netherlands
- Jul 29, 2024Phase 1 study in Healthy VolunteersNCT06532396 · 60 enrolled · Netherlands
- Nov 5, 20242 phase 1 studiesNCT06681441, NCT06714396
- Mar 5, 2025Phase 1 study in Healthy VolunteersNCT06877624 · 25 enrolled · Netherlands
- Feb 12, 2026Phase 1 study in Healthy Participant StudyNCT07421778 · 48 enrolled · Netherlands
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07421778Healthy Participant Study · Netherlands | 1 | Completed | Aug 31, 2026 | 48 |
| NCT06877624Healthy Volunteers · Netherlands | 1 | Completed | May 15, 2025 | 25 |
| NCT06714396Amyotrophic Lateral Sclerosis · Netherlands | 1 | Completed | Aug 22, 2025 | 12 |
| NCT06681441Healthy · Netherlands | 1 | Completed | Dec 24, 2024 | 24 |
| NCT06532396Healthy Volunteers · Netherlands | 1 | Completed | Dec 20, 2024 | 60 |
| NCT05667779Healthy Volunteers · Netherlands | 1 | Completed | Dec 27, 2023 | 88 |
How it is read
Names in the registry
- “QRL-101”, 5 entries
- “QRL-101 Dose A”, 1 entry
- “QRL-101 Dose B”, 1 entry
Codes read as this program: QRL101.
Conditions, from the studies’ own filings
- Amyotrophic Lateral Sclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.